AU782193B2 - Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef - Google Patents

Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef Download PDF

Info

Publication number
AU782193B2
AU782193B2 AU25810/01A AU2581001A AU782193B2 AU 782193 B2 AU782193 B2 AU 782193B2 AU 25810/01 A AU25810/01 A AU 25810/01A AU 2581001 A AU2581001 A AU 2581001A AU 782193 B2 AU782193 B2 AU 782193B2
Authority
AU
Australia
Prior art keywords
nef
dna
seq
dna vaccine
hiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU25810/01A
Other languages
English (en)
Other versions
AU2581001A (en
Inventor
Tong-Ming Fu
Xiaoping Liang
John W. Shiver
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck and Co Inc filed Critical Merck and Co Inc
Publication of AU2581001A publication Critical patent/AU2581001A/en
Application granted granted Critical
Publication of AU782193B2 publication Critical patent/AU782193B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU25810/01A 1999-12-17 2000-12-15 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef Ceased AU782193B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17244299P 1999-12-17 1999-12-17
US60/172442 1999-12-17
PCT/US2000/034162 WO2001043693A2 (fr) 1999-12-17 2000-12-15 Vaccins polynucleotidiques exprimant la proteine nef de vih-1 optimisee par codons et proteine nef de vih-1 modifiee

Publications (2)

Publication Number Publication Date
AU2581001A AU2581001A (en) 2001-06-25
AU782193B2 true AU782193B2 (en) 2005-07-07

Family

ID=22627710

Family Applications (1)

Application Number Title Priority Date Filing Date
AU25810/01A Ceased AU782193B2 (en) 1999-12-17 2000-12-15 Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef

Country Status (5)

Country Link
EP (1) EP1242441A4 (fr)
JP (1) JP2003516741A (fr)
AU (1) AU782193B2 (fr)
CA (1) CA2393861A1 (fr)
WO (1) WO2001043693A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1141314A2 (fr) 1998-12-31 2001-10-10 Chiron Corporation Polynucleotides codant pour des polypeptides antigeniques du type c du vih; polypeptides et leurs utilisations
EP1200622A4 (fr) 1999-07-06 2004-12-22 Merck & Co Inc Vaccin contre le vih comprenant un adenovirus vehiculant le gene gag
CA2398816A1 (fr) 2000-02-04 2001-08-09 Duke University Vaccin contre le virus de l'immunodeficience humaine
US6733993B2 (en) 2000-09-15 2004-05-11 Merck & Co., Inc. Enhanced first generation adenovirus vaccines expressing codon optimized HIV1-gag, pol, nef and modifications
JP5033303B2 (ja) 2001-07-05 2012-09-26 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 抗原性ｃ型ｈｉｖポリペプチドをコードするポリヌクレオチド、ポリペプチドおよびそれらの使用
PL207168B1 (pl) * 2001-09-20 2010-11-30 Glaxo Group Ltd Sekwencja nukleotydowa, wektor, białko, środek farmaceutyczny, urządzenie do podawania śródskórnego, zastosowanie sekwencji nukleotydowej i sposób wytwarzania nukleotydu
US20080154210A1 (en) 2004-05-28 2008-06-26 Oryxe Mixture for Transdermal Delivery of Low and High Molecular Weight Compounds
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
BRPI0515553A (pt) * 2004-09-17 2008-07-29 Centelion formulações lìquidas estáveis de dna de plasmìdeo
WO2009022236A2 (fr) 2007-08-16 2009-02-19 Tripep Ab Plate-forme immunogène
PL229124B1 (pl) 2015-02-10 2018-06-29 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Szczepionka DNA skierowana przeciwko wirusowi grypy H5N1, zmodyfikowana sekwencja nukleotydowa oraz zastosowanie zmodyfikowanej nukleotydowej sekwencji do wytwarzania szczepionki

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851813A (en) * 1990-07-12 1998-12-22 President And Fellows Of Harvard College Primate lentivirus antigenic compositions
WO2002022080A2 (fr) * 2000-09-15 2002-03-21 Merck & Co., Inc. Vaccins adenoviraux de premiere generation evolues, exprimant les proteines gag, pol et nef du vih-1 a optimisation des codons et leurs modifications

Also Published As

Publication number Publication date
WO2001043693A2 (fr) 2001-06-21
JP2003516741A (ja) 2003-05-20
WO2001043693A3 (fr) 2002-02-21
EP1242441A2 (fr) 2002-09-25
CA2393861A1 (fr) 2001-06-21
AU2581001A (en) 2001-06-25
EP1242441A4 (fr) 2004-04-14

Similar Documents

Publication Publication Date Title
AU734690B2 (en) Coordinate in vivo gene expression
US6534312B1 (en) Vaccines comprising synthetic genes
KR101501495B1 (ko) Ｈｉｖ-감염의 예방 및 치료를 위한 백신
US20050215508A1 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
Cease et al. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelope protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide.
ES2388527T3 (es) Vacunas de VIH basadas en Env de múltiples clados de VIH
AU728422B2 (en) Vaccines comprising synthetic genes
PL211762B1 (pl) Zastosowanie białka fuzyjnego zawierającego białka HIV Tat i HIV Nef lub polinukleotyd kodujący takie białko, białka lub polinukleotydu HIV gp120, białka lub polinukleotydu SIV Nef, adiuwanta indukującego TH1 zawierającego monofosforylolipid A lub jego pochodną i adiuwanta saponinowego oraz kompozycja szczepionki
CN107574156A (zh) 类病毒组合物颗粒及其使用方法
AU782193B2 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Nef and modified HIV-1 Nef
JP2014043468A (ja) Ｈｉｖペプチド、抗原、ワクチン組成物、免疫学的検定キット及びｈｉｖによって誘発された抗体を検出する方法
BG63126B1 (bg) Лечебни препарати на основата на нуклеинови киселини
SK71397A3 (en) Pharmaceutical compositions inducting cytotoxic t-lymphocyte response
JP2010187681A (ja) ＨＩＶに対する免疫のためのｇｐ１２０と、Ｎｅｆ及び／又はＴａｔを含むワクチン
AU779951B2 (en) Polynucleotide vaccines expressing codon optimized HIV-1 pol and modified HIV-1 pol
US20060148750A1 (en) Polynucleotide vaccines expressing codon optimized HIV-1 Pol and modified HIV-1 Pol
KR20230087583A (ko) 항원을 mhc-ii 경로로 전달하고 숙주에서 cd4+ 및 cd8+ t-세포 반응을 유도하는 새로운 세대의 렌티바이러스 벡터
CN110582295B (zh) 多种疟疾红前期抗原及其在宿主中引发保护性免疫应答的用途
US5876724A (en) Induction of neutralizing antibody against viral infection by synergy between virus envelope glycoprotein and peptides corresponding to neutralization epitopes of the glycoprotein
EP1056879A1 (fr) Vecteur autoreproducteur pour l'immunisation par l'adn contre le vih
US20040116660A1 (en) Process for the selection of hiv-1 subtype c Isolates, selected hiv-1 subtype c isolates, their genes and modifications and derivatives thereof